# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹81.69 Cr** Q4 FY26 (+79.1%) · **₹258.15 Cr** FY26 (+92.9%) * **EBITDA:** **₹9.43 Cr** Q4 FY26 (+62.5%) · **₹29.78 Cr** FY26 (+95.9%) * PAT: ₹627.9 Lakh Q4 FY26 (+83.6%) · ₹2,511.6 Lakh FY26 (+92.9% implied) * **Margins (Q4):** **11.5%** EBITDA (-120 bps) · **7.7%** PAT (+20 bps) ## B. Profitability & Margins * **Operational Efficiency:** Full-year margin expansion was driven by significant scale benefits, disciplined execution, and reduced fixed costs. * **Long-term Margin Trajectory:** Operating margins have climbed from **7% to the 11%-12% range** over the last three years, aided by inventory gains during rising price trends. * **Cost Dynamics:** Quarterly employee costs decreased significantly YoY, partly attributed to **lower director salaries**, though management is conducting a full bifurcation review. ## C. Balance Sheet & Capital Allocation * **Liquidity Management:** Secured a **₹15 Cr** debt facility from ICICI Bank to manage a temporary spike in receivables and ensure procurement during inflationary periods. * **Debt Strategy:** Management maintains a stable debt position with sufficient capacity to fund operations for the next **six months**; further borrowing will be re-evaluated after Q2. * **Equity Preservation:** No plans for further equity dilution within the next **12 to 18 months**, signaling confidence in internal cash generation and existing facilities. --- # 2. Manufacturing & Capacity ## A. Key Figures * **Ahmedabad Utilization:** **25% to 30%** current (Target: Optimal by FY27) * **Ahmedabad Revenue Potential:** **₹30 Cr to ₹35 Cr** monthly · **₹5 Cr to ₹5.5 Cr** March 2026 contribution * **Total Monthly Capacity:** **₹60 Cr** revenue potential at optimum levels * **Vasai Revenue:** **₹25 Cr to ₹28 Cr** monthly ## B. Facility Utilization & Strategy * **Ahmedabad Ramp-up:** Significant headroom for growth as the new facility scales from its current low utilization toward full operational stability by FY27. * **Pharma Sector Focus:** Capacity expansion specifically targets pharmaceutical demand across Western and Northern India. * **Margin Expansion Catalyst:** Management intends to pivot toward higher-margin strategies once the Ahmedabad site achieves stabilization. ## C. Production Expansion * **Vasai Optimization:** Existing facility is nearing full capacity, but can be expanded by an additional **20%** (approx. **₹6 Cr to ₹7 Cr**) via minor equipment upgrades. * **Growth Runway:** Combined capacities provide a clear revenue trajectory through FY27, with a strategic focus on balancing volume growth with debt recovery. ## D. Operational Efficiency * **Cost Structure:** Recent uptick in employee expenses reflects front-loaded hiring in **February and March** to support the Ahmedabad ramp-up. * **Competitive Moat:** High-volume operational model drives cost-effectiveness, maintaining a pricing advantage in the basic pharma packaging segment. --- # 3. Supply Chain & Pricing ## A. Key Figures * **Aluminum Price Inflation:** **~₹50 per unit** month-end increase (**8% to 10%**) * **Supplier Credit Terms:** **30 to 40 days** * **Order Fulfillment Cycle:** **2 to 3 days** post-PO receipt ## B. Raw Material Sourcing * **Supply Chain Resilience:** Management is mitigating global aluminum shortages by diversifying its supplier base across domestic rolling mills, with **Hindalco** as a primary partner. * **Demand Drivers:** Sustained demand for quality-compliant primary packaging (blister/strip foils) is supported by favorable domestic capacity expansion policies. ## C. Pricing Mechanisms * **Dynamic Pricing Model:** The industry eschews long-term fixed contracts in favor of **PO-to-PO transactions** with monthly rate revisions based on primary producer pricing letters. * **Cost Pass-Through Strategy:** Rising input costs in aluminum and chemicals are generally passed to pharma customers during monthly resets, though the company selectively absorbs short-term volatility to remain competitive. * **Market Normalization:** Despite daily upward pressure on raw material costs, the pharmaceutical sector has largely accepted current elevated pricing as the "new normal." ## D. Inventory & Operations * **Strategic Hedging:** Inventory levels were intentionally increased at month-end to hedge against the recent high single-digit spike in aluminum prices. * **Agile Execution:** The business model relies on monthly Purchase Orders rather than Letters of Intent, requiring high operational velocity to execute orders within the standard multi-day window. --- # 4. Strategic Initiatives ## A. Market Expansion * **Global Supply Chain Realignment:** Indian manufacturers are capturing incremental export opportunities as international firms seek stable, compliant alternatives to conflict-prone regions. * **Pharma Sector Tailwinds:** Steady growth in domestic pharmaceutical packaging is underpinned by India’s dominant role in supplying generic medicines to regulated **US and European** markets. * **Regional Scaling:** Growth strategy centers on ramping up the **Ahmedabad plant** to penetrate high-demand clusters in Gujarat, Indore, and Northern India. * **Risk-Averse Growth:** Management is prioritizing strict control over credit and debtors alongside its geographic expansion efforts. ## B. Forward Integration * **Value-Added Pivot:** Future expansion is strictly focused on forward integration, specifically through specialized printing and conversion units. * **Technological Focus:** Strategic investments will target **printing and forming technologies** to enhance product value for both domestic and export pharmaceutical clients. ## C. Competitive Moat * **Working Capital as a Barrier:** Management identifies efficient working capital management as the primary industry moat; established supplier credit terms provide a significant edge over smaller players who face **60-70 day** collection cycles. * **Volume & Efficiency Advantage:** High-volume cost effectiveness and operational efficiency allow the firm to withstand temporary shifts of **5% to 10%** of orders to lower-priced competitors without impacting long-term stability. * **Market Dynamics:** While entry barriers are low, the difficulty of exiting the industry makes long-term success dependent on the company's established scale and relationship-driven model. --- # 5. Working Capital & Customers ## A. Key Figures * **Receivables Balance:** **₹94 Cr** Period-end * **Post-Period Collections:** **₹30 Cr – ₹40 Cr** Collected within first 20 days of April * **Normalized Receivable Cycle:** **60 – 70 days** Industry standard (Equates to **₹60 Cr – ₹70 Cr** balance) * **Standard Credit Terms:** **60 – 90 days** Policy for pharma sector ## B. Receivable Cycles & Working Capital * **Liquidity Normalization:** Significant post-quarter collections have substantially reduced the elevated period-end receivable balance toward normalized levels. * **Strategic Credit Extension:** Management utilizes a standard credit window to dictate premium pricing and secure higher margins, viewing the **60-70 day** churn as vital for operational efficiency. ## C. Credit Management * **Funding Strategy:** Credit requirements for Indian pharma clients are supported by **rights issue proceeds** and **bank overdrafts**, bridging the gap necessary to secure industry business. * **Risk Mitigation:** A conservative vetting process, particularly for new prospects in **Ahmedabad**, is employed to prevent bad debts; management notes industry risk is characterized by payment delays rather than defaults. ## D. Client Relationships * **Phased Capacity Allocation:** New production capacity will be prioritized for the existing, trusted client base to leverage established relationships before pursuing new market expansion. * **Growth Strategy:** Scaling efforts focus on deepening engagement and meeting incremental requirements from current customers before pivoting to new client acquisition. --- # 6. Risks & Market Volatility ## A. Key Figures * **Aluminum Price Outlook:** **5% to 7%** projected increase in the coming fiscal year * **DSO (Days Sales Outstanding):** **120 to 150 days** for specific pharmaceutical client segments ## B. Commodity Price Risk * **Input Cost Inflation:** Severe margin pressure persists as aluminum (LME/MCX) and petrochemical derivatives like **ethyl acetate** hit record price levels. * **Strategic Stagnation:** Management is delaying aggressive new product launches to prioritize the existing portfolio amid high market volatility and raw material availability constraints. * **Supply Chain Fragility:** Ongoing global conflicts have triggered a significant surge in the cost of intermediates used in pharmaceutical packaging. ## C. Working Capital & Geopolitical Disruptions * **Liquidity Constraints:** Working capital management remains the primary business risk, requiring additional capital buffers to offset extended payment cycles from pharma clients. * **Macro-Induced Delays:** Geopolitical tensions between **Iran, Israel, and the US** disrupted Q4 FY26 operations, impacting global trade routes and supply chain stability. * **Receivable Headwinds:** High year-end receivables were driven by external disruptions to Letters of Credit (LCs) and export payment flows caused by currency and geopolitical instability. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target (FY27):** **₹450 Cr** Topline · **₹60 Cr** Monthly Run Rate * **EBITDA Margin:** **~11.5%** FY27 Target * Incremental Margins: 8% – 10% over existing products with 60–90 day credit terms * **Ahmedabad Capex:** **₹5 Cr – ₹6 Cr** Total Investment ## B. Revenue Targets & Growth Drivers * **Capacity-Led Expansion:** Management expects to double current output by March 2027, fueled by the combined throughput of the Vasai and Ahmedabad facilities. * **Ahmedabad Contribution:** The new facility is projected to deliver a significant annual revenue run rate at optimal capacity, supporting a sequential uptick in performance as it ramps up. * **Near-Term Momentum:** Following a **₹80 Cr** Q4 performance, the company anticipates steady QoQ growth, contingent on the stabilization of aluminum price volatility and material availability. ## C. Margin Sustainability & Product Mix * **Profitability Outlook:** Management aims to defend current double-digit EBITDA levels through FY27, despite raw material headwinds and market normalization timelines. * **Value-Added Strategy:** A strategic shift toward high-quality products is expected to effectively double existing margins, with concrete financial benefits projected to materialize by late FY27. * **Operational Confidence:** Existing customer demand supports the maintenance of current sales velocity, though H1 margin guidance remains cautious due to market uncertainty. ## D. Future CAPEX & Utilization * **Capacity Roadmap:** With full utilization anticipated by March 2027, the company is already evaluating post-FY27 expansion requirements to prevent growth stagnation. * **Upcoming Announcements:** A formal CAPEX plan is expected within the next **one to two quarters** to outline the next phase of industrial scaling. * **Investment Efficiency:** The Ahmedabad investment is characterized by a low capital outlay, with management expecting to recover the total cost of capital during the initial operational phase.